Or­biMed, bio­phar­ma's biggest in­vestor, clos­es $3.5B in three new pri­vate funds

One of the world’s lead­ing bio­phar­ma in­vestors has pulled in its next rounds of cash, with the funds planned to go to dozens of com­pa­nies around the world.

Or­biMed raised $3.5 bil­lion across three pri­vate in­vest­ment funds, it an­nounced Mon­day, as it con­tin­ues build­ing on its long track record in health­care and bio­phar­ma. All in all, the firm ex­pects to in­vest in at least 60 com­pa­nies across the US, Asia and Eu­rope.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER